Ethinylestradiol/levonorgestrel - Nobelpharma
Alternative Names: Jemina; NPC-16Latest Information Update: 10 Feb 2025
At a glance
- Originator Nobelpharma
- Class Alkylated estrogenic steroids; Contraceptives; Hormonal replacements; Norpregnanes; Norpregnatrienes; Small molecules
- Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Dysmenorrhoea
Most Recent Events
- 07 Feb 2025 Nobelpharma anticipates regulatory approval for Dysmenorrhoea in China in December 2028 (Nobelpharma pipeline, February 2025)
- 07 Feb 2025 Nobelpharma plans a phase III trial for Dysmenorrhoea in China (Nobelpharma pipeline, February 2025)
- 17 Oct 2018 Nobelpharma and ASKA Pharmaceutical agree to co-promote Ethinylestradiol/levonorgestrel in Japan for dysmenorrhea